Skip to main content
Figure 3 | Orphanet Journal of Rare Diseases

Figure 3

From: Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A)

Figure 3

In classical Fabry disease patients, the baseline and last follow-up LVMI (A)(C) as well as baseline, first and last follow-up serum lyso-Gb3 results (B)(D) were shown in mean ± SD. Case 3, 4, 6, 12, 13 were excluded from classical females’ LVMI (C) due to their initial normal heart size or having risk factors for LVH. There was a significant decreased of LVMI between baseline and last follow-up in classical male (A) and female FD (C) patients. Significant decreased in serum lyso-Gb3 between baseline and first follow-up results as well as baseline and last follow-up results in classical male (B) or female (D) FD patients were found. FD: Fabry disease; LVMI: left ventricular mass index; lyso-Gb3: globotriaosylsphingosine; SD: standard deviation.

Back to article page